Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an announcement.
Hemogenyx Pharmaceuticals announced that its total issued share capital consists of 5,361,267 ordinary shares, with no shares held in treasury, establishing the total number of voting rights. This information is crucial for shareholders to determine their investment requirements under financial regulations, impacting their decision-making and potentially influencing market dynamics.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, offering several distinct and complementary product candidates and platform technologies.
Average Trading Volume: 128,713
Technical Sentiment Signal: Strong Buy
Current Market Cap: £58.97M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.